<p>Until the American Thyroid Association (ATA) guidelines on management of pediatric differentiated thyroid carcinoma (DTC) became available in 2015, all children with DTC were treated like adults. This study aims to investigate the outcome of pediatric DTC and factors predicting the response to therapy in pediatric DTC managed according to adult guidelines. Clinical records of 41 children less than 18 years of age diagnosed with DTC followed from 2007 in a single center were reviewed. According to the new ATA classification for pediatric DTC, five had low-risk, 28 had intermediate-risk and eight had high-risk disease at presentation. There was no mortality or recurrence in this cohort of pediatric DTC patients and the cure rate was 46% during a mean follow-up of 44 months when they were managed according to adult guidelines. Neither the new ATA risk classification nor any clinicopathological character was identified which could predict the response to therapy. The new ATA guidelines would have avoided 27% of the radioiodine therapies given. This study showed that DTC in children managed according to adult guidelines had a good cure rate. The new ATA guidelines on pediatric DTC might have drastically reduced the number of radioiodine therapies in the affected children. Long term prospective studies are needed to validate the benefits and risks of both these approaches. © 2018 2018 Walter de Gruyter GmbH, Berlin/Boston.</p>
cited By 0
N. Bhavani, Bhadran, K., Nair, V., Menon, U. V., Pavithran, P. V., Menon, A. S., Abraham, N., Pankaj, A., and Kumar, H., “Treatment outcomes in pediatric differentiated thyroid carcinoma”, Journal of Pediatric Endocrinology and Metabolism, vol. 31, pp. 1117-1122, 2018.